252 related articles for article (PubMed ID: 28716097)
1. Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab.
Moreira RB; Hamieh L; Gjini E; Lako A; Krajewski KM; Yoon CH; Ott PA
J Immunother Cancer; 2017 Jul; 5(1):61. PubMed ID: 28716097
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy.
Plaquevent M; Greliak A; Pinard C; Duval-Modeste AB; Joly P
Melanoma Res; 2019 Jun; 29(3):311-312. PubMed ID: 31026247
[TBL] [Abstract][Full Text] [Related]
3. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
McDonald MA; Sanghvi P; Bykowski J; Daniels GA
BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
[TBL] [Abstract][Full Text] [Related]
5. Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports.
Schliep S; Agaimy A; Cavallaro A; Kiesewetter F; Schuler G; Heinzerling L
J Immunother Cancer; 2018 Jan; 6(1):2. PubMed ID: 29332608
[TBL] [Abstract][Full Text] [Related]
6. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
7. Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy.
Tietze JK; Angelova D; Heppt MV; Ruzicka T; Berking C
Exp Dermatol; 2017 Jul; 26(7):622-629. PubMed ID: 27892653
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study.
Urun Y; Yasar HA; Turna H; Esin E; Sedef AM; Alkan A; Oksuzoglu B; Ozdemir N; Sendur MN; Sezer A; Kılıckap S; Utkan G; Akman T; Akbulut H; Celik I; Abalı H
J Oncol Pharm Pract; 2019 Oct; 25(7):1658-1664. PubMed ID: 30400750
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
Eggermont AMM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbe C; Ferraresi V; Smylie M; Weber JS; Maio M; Hosein F; de Pril V; Kicinski M; Suciu S; Testori A
Eur J Cancer; 2019 Sep; 119():1-10. PubMed ID: 31400634
[TBL] [Abstract][Full Text] [Related]
10. Intraepithelial Melanoma in the Stomach After Treatment With Immune Checkpoint Blockade Therapy.
Shustef E; Torres-Cabala CA; Curry JL; Tetzlaff MT; Nagarajan P; Ivan D; Prieto VG; Aung PP
Am J Dermatopathol; 2017 Aug; 39(8):e116-e118. PubMed ID: 28248716
[TBL] [Abstract][Full Text] [Related]
11. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
Failing JJ; Finnes HD; Kottschade LA; Allred JB; Markovic SN
Melanoma Res; 2016 Dec; 26(6):609-615. PubMed ID: 27603551
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab prolongs survival in advanced melanoma.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
[No Abstract] [Full Text] [Related]
13. Diffuse recurrent cutaneous melanoma of the scalp and neck successfully treated with volumetric modulated arc therapy and concurrent ipilimumab.
Schmid RK; Harker-Murray A; Niemczyk K; Robbins JR
Pract Radiat Oncol; 2018; 8(3):174-178. PubMed ID: 29122555
[No Abstract] [Full Text] [Related]
14. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab.
Mohr P; Ascierto P; Arance A; McArthur G; Hernaez A; Kaskel P; Shinde R; Stevinson K
J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):962-971. PubMed ID: 29044660
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy.
Balatoni T; Mohos A; Papp E; Sebestyén T; Liszkay G; Oláh J; Varga A; Lengyel Z; Emri G; Gaudi I; Ladányi A
Cancer Immunol Immunother; 2018 Jan; 67(1):141-151. PubMed ID: 28988380
[TBL] [Abstract][Full Text] [Related]
16. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma.
Drysdale E; Peng Y; Nguyen P; Baetz T; Hanna TP
Melanoma Res; 2019 Dec; 29(6):635-642. PubMed ID: 30789386
[TBL] [Abstract][Full Text] [Related]
17. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
18. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.
Kähler KC; Eigentler TK; Gesierich A; Heinzerling L; Loquai C; Meier F; Meiss F; Pföhler C; Schlaak M; Terheyden P; Thoms KM; Ziemer M; Zimmer L; Gutzmer R;
Cancer Immunol Immunother; 2018 May; 67(5):825-834. PubMed ID: 29487980
[TBL] [Abstract][Full Text] [Related]
19. Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
Gambichler T; Strutzmann S; Tannapfel A; Susok L
BMC Cancer; 2017 May; 17(1):327. PubMed ID: 28499411
[TBL] [Abstract][Full Text] [Related]
20. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Yuan J; Postow MA; Wong P; Capone M; Madonna G; Khammari A; Schilling B; Sucker A; Schadendorf D; Martus P; Dreno B; Ascierto PA; Wolchok JD; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Oct; 22(19):4848-4858. PubMed ID: 27169993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]